Health Canada Joins Europe Limiting 2 Novartis Flu Vaccines!
Health Canada asked Novartis to suspend distribution of two vaccines in Canada until a full review of the situation is completed. The Public Health Agency of Canada is also recommending health care professionals in possession of these two vaccines refrain from using them until the review is complete.
Health Canada would like to provide further information to Canadians about its assessment of the voluntary suspension of use in Europe of the seasonal flu vaccines Agriflu and Fluad.
Agriflu and Fluad, two of the seasonal flu vaccines produced by Novartis, have been pulled from use in several European countries pending further examination of white floating material discovered clumping in the vaccines.
Health Canada rigorously reviewed Agriflu and Fluad for safety and effectiveness before it was authorized for use in Canada.
While clumping of the kind noted in Europe is common in vaccines, and Health Canada has previously seen such particles in other vaccines they have observed no impact on their safety or effectiveness. The Public Health Agency of Canada monitors for adverse events following immunization. To date it has received no reports of serious or unexpected adverse events related to these vaccines.
As a precautionary step, Health Canada asked Novartis to suspend distribution of the vaccines in Canada until a full review of the situation is completed. Novartis has agreed.
Agriflu and Fluad, two of the seasonal flu vaccines produced by Novartis, have been pulled from use in several European countries pending further examination of white floating material discovered clumping in the vaccines.
Health Canada rigorously reviewed Agriflu and Fluad for safety and effectiveness before it was authorized for use in Canada.
While clumping of the kind noted in Europe is common in vaccines, and Health Canada has previously seen such particles in other vaccines they have observed no impact on their safety or effectiveness. The Public Health Agency of Canada monitors for adverse events following immunization. To date it has received no reports of serious or unexpected adverse events related to these vaccines.
As a precautionary step, Health Canada asked Novartis to suspend distribution of the vaccines in Canada until a full review of the situation is completed. Novartis has agreed.
No comments:
Post a Comment
TERMS OF USE
Those who post comments are accountable for the opinions they express, and the accuracy of the information they furnish. While we encourage writers to utilize this service on our site, we also strongly suggest they treat it as public forum where good taste counts. We reserve the right to decline for approval objectionable material from this site.
Writers that include profanity or personal attacks or other inappropriate comments - such as racist language, threats or comments unrelated to the story - will not be approved. Also, entries that are unsigned or signatures by someone other than the actual writer will not be approved.
While writers can still post anonymously, we strongly suggest that they do not do so.
Opinions, guidance and other information expressed in Omemee Pigeon eFlyer comments and by contributors to the Omemee Pigeon eFlyer, represent the individuals'; own views and are not necessarily those of the Omemee Pigeon eFlyer. The Omemee Pigeon eFlyer furnishes this type of forum and does not endorse and is not accountable for statements or advice from anyone other than an designated Omemee Pigeon eFlyer spokesperson.